Take­da strikes a com­bo I/O dis­cov­ery pact with Shat­tuck Labs; Fac­ing FDA re­jec­tion, Egalet slash­es staff

⇨ Take­da’s Cam­bridge, MA-based on­col­o­gy group has struck a dis­cov­ery deal with Austin-based Shat­tuck Labs. The deal cen­ters on a com­bo im­muno-on­col­o­gy ap­proach to drug de­vel­op­ment, match­ing a check­point strat­e­gy with whip­ping up a T cell at­tack. Take­da will of­fer Shat­tuck un­spec­i­fied re­search sup­port in ex­change for con­trol of two pre-clin­i­cal and four dis­cov­ery stage can­cer pro­grams.

⇨ A few weeks af­ter get­ting a com­plete re­sponse let­ter from the FDA for its pri­or ap­proval sup­ple­ment of oxy al­ter­na­tive Ox­ay­do, the Wayne, PA-based Egalet $EGLT has be­gun cut­ting staff. In a re­lease the com­pa­ny said it would lay off 40% of its non-sales staff. The CRL proved a nasty set­back for the biotech’s stock.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.